Seppic reinforces its presence in the human vaccine adjuvant market

  • December 3, 2020
  • 2 mins of read time

Seppic reinforces its presence in the human vaccine adjuvant market

With Sepivac SWE™, Seppic is providing, through a unique offer, a vaccine adjuvant for human use that can contribute to the development of vaccine solutions to fight seasonal and pandemic influenza, as well as Covid-19.

In the context of the current health crisis, Seppic participates, together with various international partners, in the global research effort to develop a vaccine solution against Covid-19. These programs are in the pre-clinical phase and some of them should move to the clinical study stage by the end of this year. Seppic offers a unique, open-access solution for everyone - academics, biotech companies and pharmaceutical manufacturers - to accelerate the development of innovative vaccines.

Sepivac SWE™ is the result of several years of co-development with the Vaccine Formulation Institute (VFI), a non-profit organization that aims to make the safest and most effective adjuvant technologies available to all vaccine developers. This ready-to-use adjuvant is based on a technology recognized for its efficacy and good safety profile in seasonal and pandemic influenza vaccines. 

Sepivac SWE™ is currently produced by Seppic at its main production site located in Castres, in the Tarn region of France.  In order to be able to meet significant demand in crisis situations, the site's capacity will be adapted by the summer of 2021 to produce the equivalent of several hundred million doses per year.

Seppic is thus one of the first five beneficiaries of the Appel à Manifestation d’Intérêt (AMI) (Call for Expression of Interest) "health resilience", launched in June 2020. The objective of this AMI is to identify innovative projects for the industrialization of health products in order to strengthen french and European capacities, particularly in the face of the Covid-19 health crisis. It is part of the "France Relance" program, which on Thursday, November 19, 2020, dedicated a total of 31 laureates.

Jean-Baptiste Dellon, CEO of Seppic, states: “Seppic has been a player for more than 40 years in the field of vaccine adjuvants. Today, Seppic contributes to accelerate the research of innovative vaccines by proposing an adjuvant used in the composition of vaccines against Covid-19. Making this adjuvant available to the entire community of vaccine developers, at an industrial scale, is a major step to help advance vaccine research

Seppic CP Cover

Press release dated November 3, 2020